Effects of reimbursement restriction on pharmaceutical expenditures : A case of Ginkgo biloba

H. Kwon, Tae-Jin Lee
{"title":"Effects of reimbursement restriction on pharmaceutical expenditures : A case of Ginkgo biloba","authors":"H. Kwon, Tae-Jin Lee","doi":"10.4332/KJHPA.2011.21.2.249","DOIUrl":null,"url":null,"abstract":"Since May 1st in 2008, the products of ginkgo biloba extract have had to be used with the patient`s out-of-pocket payment due to reimbursement restriction guidelines. This study aims to analyze the policy effects of reimbursement restriction on pharmaceutical expenditures using interrupted time series(ITS) analysis. We retrieved monthly NHI claims data for the period between May, 2005 and December 2009. The ingredients identified as a substitute for ginkgo biloba have similar indications based on the similar pharmacological activities. The effects of changes in reimbursement scope were evaluated both for all relevant pharmaceuticals within the same therapeutic class and for 2 separate groups : ginkgo biloba`s and its substitutes. According to the study results, restrictions on reimbursement scope resulted in savings of the drug expenditures in the targeted therapeutic class. Direct restriction on ginkgo biloba was associated with a decrease in expenditure level by 60.1% and changes in trend from an average increase rate of 1.4% to an average decrease rate of 1.5% for the therapeutic class, with a dramatic decrease in expenditure level(-191.5%) for ginkgo biloba itself, but with an increased expenditure level(+50.1%) and changes in trend from an average increase rate of 2.0% to an average decrease rate of 1.0% for the substitute group. Further policy to restrict nicergoline was associated with additional decrease in expenditure level for the therapeutic class. Additionally, we could identify the balloon effect - a new policy squeezing one part results in bulging out elsewhere. After the restriction of ginkgo biloba, the utilization of and expenditures on its substitutes increased significantly. In conclusion, we demonstrated that consecutively introduced policies effectively reduced overall expenditures on the therapeutic class of interest. Some ingredients played as a substitute while others did not. Further studies need to be conducted to identify which factors determine a substitute.","PeriodicalId":253456,"journal":{"name":"Korean Journal of Health Policy and Administration","volume":"21 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2011-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Korean Journal of Health Policy and Administration","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4332/KJHPA.2011.21.2.249","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Since May 1st in 2008, the products of ginkgo biloba extract have had to be used with the patient`s out-of-pocket payment due to reimbursement restriction guidelines. This study aims to analyze the policy effects of reimbursement restriction on pharmaceutical expenditures using interrupted time series(ITS) analysis. We retrieved monthly NHI claims data for the period between May, 2005 and December 2009. The ingredients identified as a substitute for ginkgo biloba have similar indications based on the similar pharmacological activities. The effects of changes in reimbursement scope were evaluated both for all relevant pharmaceuticals within the same therapeutic class and for 2 separate groups : ginkgo biloba`s and its substitutes. According to the study results, restrictions on reimbursement scope resulted in savings of the drug expenditures in the targeted therapeutic class. Direct restriction on ginkgo biloba was associated with a decrease in expenditure level by 60.1% and changes in trend from an average increase rate of 1.4% to an average decrease rate of 1.5% for the therapeutic class, with a dramatic decrease in expenditure level(-191.5%) for ginkgo biloba itself, but with an increased expenditure level(+50.1%) and changes in trend from an average increase rate of 2.0% to an average decrease rate of 1.0% for the substitute group. Further policy to restrict nicergoline was associated with additional decrease in expenditure level for the therapeutic class. Additionally, we could identify the balloon effect - a new policy squeezing one part results in bulging out elsewhere. After the restriction of ginkgo biloba, the utilization of and expenditures on its substitutes increased significantly. In conclusion, we demonstrated that consecutively introduced policies effectively reduced overall expenditures on the therapeutic class of interest. Some ingredients played as a substitute while others did not. Further studies need to be conducted to identify which factors determine a substitute.
报销限制对医药支出的影响:以银杏为例
自2008年5月1日起,由于报销限制规定,银杏提取物产品必须患者自费使用。本研究旨在运用中断时间序列(ITS)分析,分析药费报销限制对药费支出的政策影响。我们检索了2005年5月至2009年12月期间的每月国民健康保险索赔数据。根据相似的药理活性,确定为银杏替代品的成分具有相似的适应症。对同一治疗类别内的所有相关药物和2个单独的组:银杏及其替代品,评估了报销范围变化的影响。研究结果表明,限制报销范围可以节省目标治疗类别的药物支出。直接限制银杏叶与治疗组的支出水平下降60.1%,趋势从平均增长率1.4%变化到平均下降率1.5%,其中银杏叶本身的支出水平急剧下降(-191.5%),而替代组的支出水平增加(+50.1%),趋势从平均增长率2.0%变化到平均下降率1.0%。进一步限制尼麦角林的政策与治疗类支出水平的进一步下降有关。此外,我们可以识别气球效应——挤压一部分的新政策会导致其他部分膨胀。限制银杏后,银杏代用品的利用率和支出显著增加。总之,我们证明了连续推出的政策有效地减少了对感兴趣的治疗类的总体支出。有些成分起到了替代作用,而另一些则没有。需要进行进一步的研究,以确定哪些因素决定了替代品。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信